Simon Li - SciClone Pharmaceuticals Independent Director
Director
Mr. Simon Li is an Independent Director of SciClone Pharmaceuticals, Inc., since January 2013. Most recently, Mr. Li has served as a Director since January 2013. He is currently the Chairman and Chief Executive Officer of JW Medical System Ltd., an affiliated company of Biosensors International Ltd. From 2006 to 2012, Mr. Li served in various positions at Medtronic, a global medical technology company, including as the Global Officer and Member of the Executive Committee of Medtronic and President, Greater China and Chairman of the Board, MedtronicWeigao JV. Prior to Medtronic, from 1999 to 2005, Mr. Li served in various positions at Johnson Johnson Medical, China including International Vice President, North AsiaNew Business Development, Asia PacificStrategic Medical Affairs, Asia Pacific. Earlier in his career with JJ, he held the positions of International Vice President, North Asia, Managing Director, China and Hong Kong, and Managing Director, China. Prior to JJ, Mr. Li was President and Chief Operating Officer of the ConvaTec business with BristolMyers Squibb in Hong Kong. He also served as General Manager of the pharmaceutical distributor Y.C. Woo Co., Ltd. in Hong Kong. He earned a Bachelor of Arts degree in social sciences from the University of Hong Kong, an M.B.A. degree from Henley Management, and an advanced E.M.B.A. from Harvard Business School. since 2013.
Age | 64 |
Tenure | 11 years |
Professional Marks | MBA |
Phone | 650 358-3456 |
Web | www.sciclone.com |
SciClone Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.16 % which means that it generated a profit of $0.16 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.19 %, meaning that it created $0.19 on every $100 dollars invested by stockholders. SciClone Pharmaceuticals' management efficiency ratios could be used to measure how well SciClone Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 2.73 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. SciClone Pharmaceuticals has a current ratio of 8.19, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist SciClone Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, SciClone Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like SciClone Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for SciClone to invest in growth at high rates of return. When we think about SciClone Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | DIRECTOR Age | ||
Robert McCullough | Primerica | 74 | |
Maria Marques | Marsh McLennan Companies | 58 | |
Gary Crittenden | Primerica | 67 | |
Sherman Edmiston | Albertsons Companies | 53 | |
Cecil Conlee | National Beverage Corp | 80 | |
Jennifer Carter | Hanover Foods | 44 | |
C Chambliss | Primerica | 76 | |
Samuel Hathorn | National Beverage Corp | 73 | |
Deborah Hopkins | Marsh McLennan Companies | 66 | |
Rodney McMullen | Cincinnati Financial | 53 | |
Patrick Kriegshauser | Albertsons Companies | 54 | |
Larry Webb | Cincinnati Financial | 62 | |
Paul Hanrahan | Albertsons Companies | 57 | |
Saxby Chambliss | Primerica | 74 | |
Douglas Skidmore | Cincinnati Financial | 55 | |
James Sturgill | Hanover Foods | 67 | |
Gregory Ziegler | Cincinnati Financial | N/A | |
Allen Gibson | Albertsons Companies | 54 | |
Lloyd Yates | Marsh McLennan Companies | 60 | |
Marc Oken | Marsh McLennan Companies | 74 | |
Peter Wold | Albertsons Companies | 67 |
Management Performance
Return On Equity | 0.19 | |||
Return On Asset | 0.16 |
SciClone Pharmaceuticals Leadership Team
Elected by the shareholders, the SciClone Pharmaceuticals' board of directors comprises two types of representatives: SciClone Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SciClone. The board's role is to monitor SciClone Pharmaceuticals' management team and ensure that shareholders' interests are well served. SciClone Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SciClone Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Meng, VP of Compliance and General Counsel | ||
Richard Hawkins, Independent Director | ||
Gregg Lapointe, Independent Director | ||
Hong Zhao, CEO of China Operations | ||
Wilson Cheung, CFO, Sr. VP of Fin. and Secretary | ||
Nancy Chang, Director | ||
Anthony Lapointe, Independent Director | ||
Lan Xie, VP of Fin. and CFO of China Operations | ||
Raymond Low, Vice President - Finance, Controller | ||
Robert King, Senior Vice President - Product Development and Supply Chain | ||
Simon Li, Independent Director | ||
Jon Saxe, Independent Chairman of the Board | ||
Friedhelm Blobel, CEO and President Executive Director and Member of Bus. Devel. Committee |
SciClone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is SciClone Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.19 | |||
Return On Asset | 0.16 | |||
Profit Margin | 0.21 % | |||
Operating Margin | 25.82 % | |||
Current Valuation | 422 M | |||
Shares Outstanding | 52.19 M | |||
Shares Owned By Insiders | 10.03 % | |||
Shares Owned By Institutions | 79.96 % | |||
Number Of Shares Shorted | 1.21 M | |||
Price To Earning | 13.75 X |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in SciClone Stock
If you are still planning to invest in SciClone Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the SciClone Pharmaceuticals' history and understand the potential risks before investing.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |